GPT-Rosalind (OpenAI) vs Wingman (Emergent)
Which one should you pick? Here's the full breakdown.
GPT-Rosalind (OpenAI)
OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)
Wingman (Emergent)
Emergent's messaging-first personal AI agent -- launched 2026-04-15 from the India vibe-coding startup ($70M raise, $300M valuation). Positioned as an OpenClaw alternative with safer defaults
| Category | GPT-Rosalind (OpenAI) | Wingman (Emergent) |
|---|---|---|
| Ease of Use | 3.0 | 8.5 |
| Output Quality | 9.0 | 8.0 |
| Value | 7.0 | 8.5 |
| Features | 8.0 | 7.5 |
| Overall | 6.8 | 8.1 |
Pricing Comparison
| Feature | GPT-Rosalind (OpenAI) | Wingman (Emergent) |
|---|---|---|
| Free Tier | No | Yes |
| Starting Price | Invite only | $0 |
Which Should You Pick?
Pick GPT-Rosalind (OpenAI) if...
- ✓Higher output quality (9 vs 8)
Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.
Visit GPT-Rosalind (OpenAI)Pick Wingman (Emergent) if...
- ✓Easier to use (8.5 vs 3)
- ✓Better value for money (8.5/10)
- ✓Has a free tier
Users who want the OpenClaw messaging-first UX without running their own infrastructure, especially in India, Southeast Asia, Latin America, and other markets where WhatsApp is the dominant messaging platform. Good for non-technical users who want a real personal agent without the terminal tax.
Visit Wingman (Emergent)Our Verdict
Wingman (Emergent) is the clear winner here with 8.1/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but Wingman (Emergent) outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.